Ho-Jin Shin1, Kihyun Kim2, Je-Jung Lee3, Moo-Kon Song1, Eun Yup Lee4, Sang Hyuk Park4, Sun-Hee Kim5, Mi-Ae Jang5, Seok Jin Kim6, Joo Seop Chung1. 1. Division of Hematology-Oncology, Department of Internal Medicine, School of Medicine, Pusan National University, Medical Research Institute, Pusan National University Hospital, Busan, South Korea. 2. Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea. Electronic address: kihyunk@smc.samsung.co.kr. 3. Department of Internal Medicine, Chonnam National University Hwasun Hospital, Hwasun. 4. Department of Laboratory Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, South Korea. 5. Department of Laboratory Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea. 6. Department of Medicine, Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea.
Abstract
INTRODUCTION: Fluorescence in-situ hybridization (FISH)-detected abnormalities, including del(17p), del(13q), and t(4;14), have been associated with inferior prognosis. However, there are few data about the prognostic significance of cytogenetic abnormalities for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients with extramedullary plasmacytoma (EMP). PATIENTS AND METHODS: Between April 2004 and December 2012, 290 MM patients underwent ASCT at 3 centers. FISH data for bone marrow samples obtained at diagnosis were available for 58 patients who had EMP at diagnosis or during treatment. RESULTS: The t(11;14), t(4;14), del(13q), and 1q gain abnormalities were seen in 14.9%, 6.3%, 25.6%, and 42.9%, respectively. No t(14;16) or del(17p) cytogenetic abnormality was detected in the examined patients. Patients with t(11;14) had a lower response rate compared to patients with other cytogenetic abnormalities. EMP-specific relapse was higher in patients with t(11;14) than in patients with other cytogenetic abnormalities (42.9% vs. 10%-33.3%). Each of the 4 cytogenetic abnormalities predicted shorter median progression-free survival (6-12 months vs. 27-37 months) and shorter overall survival (16-22 months vs. 68 months or not reached) compared to no cytogenetic abnormality. The t(11;14) translocation was an important prognostic factor for both progression-free survival (hazard ratio, 25.154; P < .001) and overall survival (hazard ratio, 7.484; P = .024) in the multivariate analysis. CONCLUSION: In the current study, t(11;14), t(4;14), del(13q), and 1q gain were associated with worse survival in MM patients with EMP. The role of t(11;14) as a prognostic parameter for ASCT in MM patients with EMP should be confirmed with a large, well-designed study.
INTRODUCTION: Fluorescence in-situ hybridization (FISH)-detected abnormalities, including del(17p), del(13q), and t(4;14), have been associated with inferior prognosis. However, there are few data about the prognostic significance of cytogenetic abnormalities for autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients with extramedullary plasmacytoma (EMP). PATIENTS AND METHODS: Between April 2004 and December 2012, 290 MMpatients underwent ASCT at 3 centers. FISH data for bone marrow samples obtained at diagnosis were available for 58 patients who had EMP at diagnosis or during treatment. RESULTS: The t(11;14), t(4;14), del(13q), and 1q gain abnormalities were seen in 14.9%, 6.3%, 25.6%, and 42.9%, respectively. No t(14;16) or del(17p) cytogenetic abnormality was detected in the examined patients. Patients with t(11;14) had a lower response rate compared to patients with other cytogenetic abnormalities. EMP-specific relapse was higher in patients with t(11;14) than in patients with other cytogenetic abnormalities (42.9% vs. 10%-33.3%). Each of the 4 cytogenetic abnormalities predicted shorter median progression-free survival (6-12 months vs. 27-37 months) and shorter overall survival (16-22 months vs. 68 months or not reached) compared to no cytogenetic abnormality. The t(11;14) translocation was an important prognostic factor for both progression-free survival (hazard ratio, 25.154; P < .001) and overall survival (hazard ratio, 7.484; P = .024) in the multivariate analysis. CONCLUSION: In the current study, t(11;14), t(4;14), del(13q), and 1q gain were associated with worse survival in MMpatients with EMP. The role of t(11;14) as a prognostic parameter for ASCT in MMpatients with EMP should be confirmed with a large, well-designed study.
Authors: L Kumar; R Gogi; A K Patel; A Mookerjee; R K Sahoo; P S Malik; A Sharma; S Thulkar; R Kumar; A Biswas; O D Sharma; R Gupta Journal: Bone Marrow Transplant Date: 2017-08-14 Impact factor: 5.483
Authors: A Lakshman; M Alhaj Moustafa; S V Rajkumar; A Dispenzieri; M A Gertz; F K Buadi; M Q Lacy; D Dingli; A L Fonder; S R Hayman; M A Hobbs; W I Gonsalves; Y L Hwa; P Kapoor; N Leung; R S Go; Y Lin; T V Kourelis; J A Lust; S J Russell; S R Zeldenrust; R A Kyle; S K Kumar Journal: Leukemia Date: 2017-06-27 Impact factor: 11.528
Authors: Susan Bal; Shaji K Kumar; Rafael Fonseca; Francesca Gay; Vania Tm Hungria; Ahmet Dogan; Luciano J Costa Journal: Am J Cancer Res Date: 2022-07-15 Impact factor: 5.942
Authors: Talha Badar; Parameswaran Hari; Omar Dávila; Raphael Fraser; Baldeep Wirk; Binod Dhakal; Cesar O Freytes; Cesar Rodriguez Valdes; Cindy Lee; David H Vesole; Ehsan Malek; Gerhard C Hildebrandt; Heather Landau; Hemant S Murthy; Hillard M Lazarus; Jesus G Berdeja; Kenneth R Meehan; Melhem Solh; Miguel Angel Diaz; Mohamed A Kharfan-Dabaja; Natalie S Callander; Nosha Farhadfar; Qaiser Bashir; Rammurti T Kamble; Ravi Vij; Reinhold Munker; Robert A Kyle; Saurabh Chhabra; Shahrukh Hashmi; Siddhartha Ganguly; Sundar Jagannath; Taiga Nishihori; Yago Nieto; Shaji Kumar; Nina Shah; Anita D'Souza Journal: Cancer Date: 2020-09-23 Impact factor: 6.860